

VERSION WITH MARKINGS TO SHOW CHANGES MADE
IN THE SPECIFICATION

Page 1, insert after the Title and prior to the first line the sentence. --

This application is a continuation-in-part of U.S. Application serial no.
90/700,165, which was filed on November 9, 2000 which was based on
PCT/GB00/01787 application filed on May 10, 2000 which claims priority from
U.S. provisional application 60/133,355 filed on May 10, 1999. --

IN THE CLAIMS

Please amend claim 1 as follows:

1. (Twice Amended) A method of treating ~~or preventing~~ sexual dysfunction which comprises administering to a subject suffering ~~or liable to~~ suffer therefrom and in need of treatment ~~or prevention~~ an effective amount of a bombesin receptor antagonist.

Please amend claim 16 as follows:

16. (Amended) The method of Claim 1, wherein the bombesin receptor antagonist is administered in combination with ~~a compound that promotes production of NO~~ L-arginine or a PDE 5 inhibitor.

Please amend claim 19 as follows:

19. (Amended) The method of claim 1, which comprises administering to a subject a bombesin receptor antagonist in combination with a second agent comprising catecholamine agonist, a 5HT₂ antagonist, neurotransmitter agonist ~~or antagonist~~, a monoamine synthesis modifier, or a monoamine metabolism or uptake modifier useful for the treatment of sexual dysfunction.

Please amend claim 20 as follows:

20. (Amended) The method of claim 19, wherein the second agent

~~neurotransmitter agonist or antagonist~~ is selected from quinelorane, ritaneserin, para-chlorophenylalanine or imipramine.

Please amend claim 23 as follows:

23. (Amended) The method of claim 19 wherein the bombesin receptor antagonist and the catecholamine agonist, 5HT₂ antagonist, ~~neurotransmitter agonist or antagonist,~~ monoamine synthesis modifier, or monoamine metabolism or uptake modifier are simultaneously administered to the subject in the form of a composition containing a unit dose of the bombesin receptor antagonist, a unit dose of the catecholamine agonist, 5HT₂ antagonist, ~~neurotransmitter agonist or antagonist,~~ monoamine synthesis modifier, or monoamine metabolism or uptake modifier and a pharmaceutically acceptable carrier or diluent.

Please Cancel Claim 32.

Please amend claim 33 as follows:

33. (Amended) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor antagonist.

Please amend claim 36 as follows:

36. (Amended) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a catecholamine agonist or 5HT₂ antagonist ~~neurotransmitter modulator~~.

Please Cancel Claim 43.

Please amend claim 44 as follows:

44. (Amended) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor antagonist.

Please amend claim 46 as follows:

46. (Amended) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a catecholamine agonist, 5HT₂ antagonist, neurotransmitter modulator.